Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7
July 24, 2019 16:05 ET | Dynavax Technologies Corporation
BERKELEY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on developing novel vaccines, will report...
dynavax_logo.png
Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  
June 03, 2019 16:05 ET | Dynavax Technologies Corporation
BERKELEY, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President,...
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
June 03, 2019 14:15 ET | Dynavax Technologies Corporation
Progression Free Survival (PFS) rate of 18-months in 72% of patientsClinical efficacy in patients with immunologically cold tumor at baselineThe combination of SD-101 and pembrolizumab was...
dynavax_logo.png
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
June 01, 2019 14:15 ET | Dynavax Technologies Corporation
24% overall response rate in ITT populationResponses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated BERKELEY, Calif., June ...
dynavax_logo.png
Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
May 23, 2019 16:45 ET | Dynavax Technologies Corporation
Company will explore strategic alternatives for its immuno-oncology programsCompany will align its resources to focus on HEPLISAV-B commercializationEddie Gray, CEO, to retire BERKELEY, Calif., May ...
dynavax_logo.png
Dynavax Announces First Quarter 2019 Financial Results
May 08, 2019 16:05 ET | Dynavax Technologies Corporation
First quarter 2019 HEPLISAV-B® net product revenue of $5.6 millionConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT BERKELEY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Dynavax...
dynavax_logo.png
Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in Adults With End-Stage Renal Disease
May 02, 2019 17:00 ET | Dynavax Technologies Corporation
BERKELEY, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and...
dynavax_logo.png
Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8
April 25, 2019 16:05 ET | Dynavax Technologies Corporation
BERKELEY, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel...
dynavax_logo.png
Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
April 18, 2019 16:05 ET | Dynavax Technologies Corporation
BERKELEY, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel...
dynavax_logo.png
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
April 02, 2019 13:00 ET | Dynavax Technologies Corporation
Using an investigational safety treatment regimen, inhaled DV281 in combination with systemic nivolumab was well tolerated in a population of heavily pre-treated NSCLC patientsTarget engagement was...